FY2028 Earnings Forecast for CLDX Issued By Leerink Partnrs

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Analysts at Leerink Partnrs dropped their FY2028 earnings per share estimates for Celldex Therapeutics in a research note issued to investors on Wednesday, November 6th. Leerink Partnrs analyst T. Smith now forecasts that the biopharmaceutical company will post earnings per share of $1.04 for the year, down from their prior estimate of $1.24. The consensus estimate for Celldex Therapeutics' current full-year earnings is ($2.50) per share.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.64) EPS for the quarter, topping analysts' consensus estimates of ($0.69) by $0.05. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 20.41%. The company had revenue of $3.19 million during the quarter, compared to analysts' expectations of $1.44 million.

Several other research firms also recently weighed in on CLDX. The Goldman Sachs Group started coverage on Celldex Therapeutics in a research note on Monday, September 30th. They set a "neutral" rating and a $45.00 price target on the stock. HC Wainwright reiterated a "buy" rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research report on Thursday. Wolfe Research lowered shares of Celldex Therapeutics from an "outperform" rating to a "peer perform" rating in a research report on Friday, September 27th. Cantor Fitzgerald restated an "overweight" rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research note on Monday, September 16th. Finally, Wells Fargo & Company upgraded shares of Celldex Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Thursday, September 26th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Celldex Therapeutics has an average rating of "Moderate Buy" and an average price target of $62.25.

Celldex Therapeutics Stock Down 0.5 %

Shares of CLDX traded down $0.14 during trading hours on Friday, reaching $26.33. 410,340 shares of the company traded hands, compared to its average volume of 868,227. The business has a fifty day moving average price of $33.90 and a 200-day moving average price of $35.90. Celldex Therapeutics has a 12-month low of $24.43 and a 12-month high of $53.18. The stock has a market capitalization of $1.75 billion, a P/E ratio of -10.37 and a beta of 1.60.

Hedge Funds Weigh In On Celldex Therapeutics

A number of hedge funds have recently bought and sold shares of CLDX. Novo Holdings A S raised its stake in shares of Celldex Therapeutics by 13.4% during the 3rd quarter. Novo Holdings A S now owns 963,663 shares of the biopharmaceutical company's stock worth $32,755,000 after buying an additional 113,663 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Celldex Therapeutics by 631.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical company's stock valued at $129,571,000 after purchasing an additional 2,664,915 shares in the last quarter. Swiss National Bank grew its position in shares of Celldex Therapeutics by 17.8% in the first quarter. Swiss National Bank now owns 114,300 shares of the biopharmaceutical company's stock valued at $4,797,000 after purchasing an additional 17,300 shares during the period. Bellevue Group AG increased its stake in shares of Celldex Therapeutics by 15.7% during the first quarter. Bellevue Group AG now owns 2,796,615 shares of the biopharmaceutical company's stock worth $117,374,000 after purchasing an additional 380,319 shares in the last quarter. Finally, AlphaCentric Advisors LLC raised its position in shares of Celldex Therapeutics by 23.4% during the 2nd quarter. AlphaCentric Advisors LLC now owns 47,500 shares of the biopharmaceutical company's stock worth $1,758,000 after purchasing an additional 9,000 shares during the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.